PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Temporary disruption: Measureable negative effect on demand for less than a month when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent; Not feasible: Eradication extremely unlikely
OVERVIEW
Porcine reproductive and respiratory syndrome (PRRS) remains one of the most globally significant swine diseases due to its wide distribution, potentially catastrophic economic impact, and lack of consistently effective control measures. The disease is caused by two distinct species of RNA viruses in the family Arteriviridae: PRRSV-1 (Betaarterivirus europensis, predominant in Europe) and PRRSV-2 (Betaarterivirus americense, predominant in the Americas and Asia). The two prototype strains (Lelystad virus and VR-2332) were discovered around 1991 but differ by approximately 44% in nucleotide sequences, suggesting their ancestors evolved independently for an extended period in an as-yet-unidentified host. Both species exhibit exceptionally high mutation and recombination rates, resulting in continuous emergence of novel isolates that limit vaccine efficacy. PRRSV is immunosuppressive by nature, rendering infected pigs susceptible to secondary infections. The combination of viral persistence (infectious virus detected up to 157 days post-infection, viral RNA up to 251 days) and lethality for late-gestation fetuses complicates control efforts. Clinical presentation ranges from subclinical to devastating depending on isolate virulence, host genetics, immune status, concurrent infections, and environmental factors. Highly pathogenic (HP-PRRSV) isolates have emerged periodically, including strains in China (2006) causing severe disease with high mortality. In breeding herds, PRRS causes late-gestation abortions, premature parturition, and weak congenitally infected piglets. In growing pigs, it causes respiratory disease and predisposes to secondary bacterial infections (porcine respiratory disease complex). Annual US losses have been estimated at $664 million, making PRRS arguably the most economically important infectious disease of swine in North America.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
The chapter explicitly states: "PRRSV is not infectious for humans or human origin cells and currently has no public health significance." Despite decades of extensive human exposure through farming, veterinary practice, and laboratory work with this globally distributed virus, no human infections have been documented. PRRSV poses no foodborne risk to consumers of pork products.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
PRRSV does not infect humans through any route. The virus replicates only in a subset of monocyte-derived cells expressing CD163, which functions as the obligate receptor. Human cells lack the appropriate receptor configuration for PRRSV entry and replication. No occupational infections have been documented among farm workers, veterinarians, or laboratory personnel despite extensive exposure over more than three decades since the virus was first identified.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity
PRRSV has exceptional capacity to spread despite biosecurity measures due to multiple factors: (1) Multiple transmission routes: intranasal, intramuscular, oral, intrauterine, vaginal, and venereal (semen); (2) Low infectious dose: approximately 20 PRRSV particles for parenteral infection; (3) Prolonged shedding: virus shed in all secretions and excretions; shedding in semen increases potential for long-distance transmission; (4) Persistent infection: infectious virus detected up to 157 days post-inoculation, viral RNA up to 251 days; (5) Aerosol transmission: documented spread via airborne route, prompting some operations to install air filtration systems; (6) Multiple indirect routes: fomites (boots, coveralls, equipment, needles), transport vehicles, feed, and insects; (7) Vertical transmission: efficient transplacental transmission occurs during late gestation (after GD 72), with congenitally infected piglets shedding virus for extended periods. The chapter notes that in US swine-dense areas, "55% of groups of growing pigs that are negative for PRRSV at placement become positive prior to marketing" despite biosecurity efforts. Even with air filtration, which provides approximately 80% reduction in risk, novel PRRSV introduction still occurs. Machine learning algorithms are being developed to predict outbreak risks, but preventing PRRSV introduction "requires vigilance" and complete prevention remains elusive in pig-dense regions.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Clinical diagnosis can be challenging because: clinical signs vary from subclinical to severe depending on isolate, host factors, and concurrent infections; respiratory signs overlap extensively with other pathogens in the porcine respiratory disease complex; and reproductive losses have multiple potential etiologies. However, once PRRSV is suspected, laboratory confirmation is straightforward with multiple well-established methods: (1) Virus isolation in PAMs, MARC-145 cells, or ZMAC cells; (2) Real-time RT-PCR providing sensitive, specific, high-throughput detection with quantification capability; (3) Antigen detection via immunohistochemistry or fluorescent antibody staining in tissues; (4) Serology via commercial ELISA (widely available), IFA, or virus neutralization tests; (5) Sequencing (ORF5 or whole genome) for genetic characterization and epidemiological investigation. Multiple specimen types are suitable including serum, tissues, oral fluids, processing fluids, and tongue tips from dead animals. The chapter notes that "the absence of clinical signs does not confirm that a population is free of PRRSV"—subclinical infection is common, and persistent infection cannot be easily diagnosed, contributing to transmission through nonclinical carriers.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
PRRSV causes catastrophic losses through multiple mechanisms affecting all production phases: (1) Breeding herd losses: late-gestation abortions, premature parturition (GD 110-113), stillbirths, mummified fetuses, weak congenitally infected piglets, increased preweaning mortality (often approaching 100% with HP-PRRSV), delayed return to estrus, hypo/agalactia; sow mortality typically low but can reach 10% with highly virulent isolates; (2) Nursery/grower losses: anorexia, lethargy, respiratory disease (hyperpnea, dyspnea), 12-20% mortality in uncomplicated cases, reduced average daily gain; HP-PRRSV causes prolonged high fever (40-42°C), rapid weight loss, and high mortality; (3) Secondary infections: PRRSV-induced immunosuppression (reduced phagocytic and bacterial killing capacity of macrophages) predisposes to bacterial and viral coinfections, exacerbating the porcine respiratory disease complex; (4) Prolonged recovery: with effective interventions, herd productivity returns to pre-outbreak levels in 4-5 months, but ongoing endemic circulation causes continuous subclinical losses. The economic impact is enormous—US losses were estimated at $664 million annually, with $5.70 per pig placed lost due to lateral PRRSV introduction in growing pigs. The chapter describes PRRS as "one of the most globally significant swine diseases due to its wide distribution, potentially catastrophic economic impact, and the lack of consistently effective control measures."
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Temporary disruption: Measureable negative effect on demand for less than a month when disease occurs on one or more farms
PRRSV is not a WOAH-listed disease, meaning detection does not trigger mandatory international trade restrictions or regulatory notifications. However, market impacts occur through: (1) Trading partner requirements: some countries maintain PRRSV-free status or have import restrictions related to PRRSV; (2) Premium market access: PRRSV-negative herds may access premium markets or breeding stock sales unavailable to positive herds; (3) Internal market segmentation: the herd classification system (Positive Unstable, Positive Stable, Provisional Negative, Negative) affects movement of breeding stock and weaned pigs; (4) Regional elimination programs: regions or countries attempting PRRSV elimination face economic impacts from control measures. Several countries have achieved PRRSV-free status (Chile, Sweden, Switzerland, Hungary) but most have experienced periodic reintroductions. The widespread endemic nature of PRRSV in major pork-producing countries means the primary economic impact is production losses rather than trade restrictions.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
PRRSV is a viral pathogen (positive-sense single-stranded RNA arterivirus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns in the traditional sense. However, PRRSV exhibits exceptional genetic diversity and evolution: high mutation rates characteristic of RNA viruses; frequent recombination events that can involve any genomic region; emergence of quasi-species (clouds of mutationally distinct genomes) within infected hosts; and evolution of variants capable of escaping existing neutralizing antibody responses (explaining viral rebound in some pigs). This genetic plasticity contributes to vaccine escape and the continuous emergence of novel variants, but represents viral evolution rather than antimicrobial resistance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
PRRSV itself is not treated with antimicrobials, but PRRSV-induced immunosuppression predisposes pigs to secondary bacterial infections that often require antimicrobial treatment. The chapter notes that PRRSV "renders infected pigs susceptible to secondary infections and increasing the severity of clinical disease" and that "a higher than usual incidence of endemic diseases specific to the farm is common" during PRRSV outbreaks. Secondary pathogens commonly requiring treatment include Streptococcus suis, Haemophilus parasuis (Glässer's disease), Mycoplasma hyopneumoniae, Pasteurella multocida, and Actinobacillus pleuropneumoniae. In endemic herds with ongoing PRRSV circulation in the porcine respiratory disease complex, antimicrobial use for bacterial coinfections may be routine and population-based rather than individual animal treatment, contributing to selection pressure for antimicrobial resistance development.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
The chapter states: "Specific treatments for PRRS are not available." No antiviral drugs exist for PRRSV. Management is entirely preventive (biosecurity, vaccination, gilt acclimation) or supportive (treating secondary bacterial infections). Pigs that survive clear the infection through their own immune response over weeks to months. The lack of effective treatments is a major factor in the difficulty of PRRS control—once infection occurs, the virus must run its course through the population.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent
Multiple commercial vaccines are available but with significant limitations: (1) Modified live virus (MLV) vaccines: available for both PRRSV-1 (Europe, Asia) and PRRSV-2 (globally); induce more efficacious immune response than killed vaccines; provide homologous protection and variable cross-protection; approved for use in breeding animals (some products); (2) Inactivated vaccines: generally considered to provide poor protection alone but may stimulate anamnestic response when used with MLV or in previously infected animals. Key limitations include: (1) Limited cross-protection: vaccines based on specific strains are dependent on cross-protective immunity; genetic diversity of field isolates frequently results in inadequate cross-protection, particularly for reproductive PRRS where "outbreaks are known to occur in herds with solid immunity induced by regular vaccination or live virus inoculation programs"; (2) Safety concerns: field reports suggest possible reversion to virulence by some attenuated vaccine viruses; recombination between vaccine and field strains documented; (3) Variable field efficacy: "in the field, vaccines are variably effective, potentially related to differences across commercial products and how they are used, differences in the virus variants circulating in different regions, and/or inadequate cross-protection"; (4) No DIVA capability: current assays cannot differentiate antibodies from wild-type infection versus MLV vaccination; (5) Maternal antibody interference: may reduce vaccine efficacy in piglets. Live virus inoculation (LVI) with farm-specific isolates is used in some regions but has inherent risks and is illegal in some countries.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
PRRSV eradication from the US pig population is not feasible because: (1) Widespread endemic distribution: PRRSV is distributed globally and endemic in virtually all major pig-producing regions; (2) Persistent infection: virus persists in lymphoid tissues for months, with infected pigs shedding intermittently; "persistent infection cannot be easily diagnosed, contributing to direct transmission of PRRSV through nonclinical carriers"; (3) Multiple transmission routes: direct contact, aerosol, semen, fomites, insects, feed—controlling all routes simultaneously is impractical; (4) Genetic diversity and evolution: continuous emergence of novel variants through mutation and recombination; (5) Incomplete vaccine protection: vaccines cannot prevent all infections or transmission; (6) Industry structure: movement of pigs, semen, feed, and equipment between operations maintains viral circulation; (7) Economic barriers: elimination requires extended herd closure (200+ days recommended) or depopulation/repopulation—costs are prohibitive at national scale. While individual herds can achieve PRRSV-negative status through herd closure/rollover or depopulation/repopulation, and regional elimination programs have been attempted, maintaining freedom "requires vigilance" and reintroductions occur. Countries that achieved eradication (Chile, Sweden, Switzerland, Hungary) have "experienced periodic reintroductions followed by efforts to re-eradicate the virus." In North America, regional elimination projects have had "limited success" due to the coordination and collaboration required. The practical approach is control (achieving Positive Stable status) rather than elimination for most operations.